| Literature DB >> 29990311 |
Robert Albero1, Anna Enjuanes2,3, Santiago Demajo1, Giancarlo Castellano4, Magda Pinyol2,3, Noelia García1, Cristina Capdevila1, Guillem Clot1, Helena Suárez-Cisneros2, Mariko Shimada5,6, Kennosuke Karube5,6, Mónica López-Guerra1,3,6, Dolors Colomer1,3,6, Sílvia Beà1,3, José Ignacio Martin-Subero1,3, Elías Campo1,3,6, Pedro Jares1,3,4,6.
Abstract
Cyclin D1 is an oncogene frequently overexpressed in human cancers that has a dual function as cell cycle and transcriptional regulator, although the latter is widely unexplored. Here, we investigated the transcriptional role of cyclin D1 in lymphoid tumor cells with cyclin D1 oncogenic overexpression. Cyclin D1 showed widespread binding to the promoters of most actively transcribed genes, and the promoter occupancy positively correlated with the transcriptional output of targeted genes. Despite this association, the overexpression of cyclin D1 in lymphoid cells led to a global transcriptional downmodulation that was proportional to cyclin D1 levels. This cyclin D1-dependent global transcriptional downregulation was associated with a reduced nascent transcription and an accumulation of promoter-proximal paused RNA polymerase II (Pol II) that colocalized with cyclin D1. Concordantly, cyclin D1 overexpression promoted an increase in the Poll II pausing index. This transcriptional impairment seems to be mediated by the interaction of cyclin D1 with the transcription machinery. In addition, cyclin D1 overexpression sensitized cells to transcription inhibitors, revealing a synthetic lethality interaction that was also observed in primary mantle cell lymphoma cases. This finding of global transcriptional dysregulation expands the known functions of oncogenic cyclin D1 and suggests the therapeutic potential of targeting the transcriptional machinery in cyclin D1-overexpressing tumors.Entities:
Keywords: Cancer; Cell Biology; Transcription
Mesh:
Substances:
Year: 2018 PMID: 29990311 PMCID: PMC6118591 DOI: 10.1172/JCI96520
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808